Reference : Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-...
Scientific journals : Article
Human health sciences : Hematology
Human health sciences : Immunology & infectious disease
Human health sciences : Surgery
http://hdl.handle.net/2268/22914
Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning
English
Baron, Frédéric mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie]
Sandmaier, Brenda M. [> > > >]
Storer, Barry E. [> > > >]
Maris, Michaël B. [> > > >]
Langston, Amelia A. [> > > >]
Lange, Thoralf [> > > >]
Petersdorf, Effie [> > > >]
Bethge, Wolfgang [> > > >]
Maziarz, Richard T. [> > > >]
McSweeney, Peter A. [> > > >]
Pulsipher, Michael A. [> > > >]
Wade, James C. [> > > >]
Chauncey, Thomas R. [> > > >]
Sbizuru, Judith A. [> > > >]
Sorror, Mohamed L. [> > > >]
Woolfrey, Ann E. [> > > >]
Maloney, David G. [> > > >]
Storb, Rainer [> > > >]
Sep-2007
Biology of Blood & Marrow Transplantation
Elsevier Science Inc
13
9
1041-1048
Yes (verified by ORBi)
International
1083-8791
New York
[en] unrelated hematopoietic cell transplantation ; mycophenolate mofetil ; cyclosporine ; graft-versus-host disease
[en] We previously reported data from 103 patients with hematologic malignancies (median age 54 years) who received peripheral blood stem cell (PBSC) grafts from HLA-matched unrelated donors after nonmycloablative conditioning and were given postgrafting immunosuppression consisting of mycophenolate mofetil (MMF; administered from day 0 until day + 40 with taper through day + 96) and cyclosporine (CSP; given from day -3 to day + 100, with taper through day 180) (historical patients). The incidences of grade II-IV acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were 52% and 49%, respectively, and the 1-year probabilities of relapse, nonrelapse mortality (NRM), and progression-free survival (PFS) were 26%, 18%, and 56%, respectively. Here, we treated 71 patients with hematologic malignancies (median age 56 years) with unrelated PBSC grafts and investigated whether postgrafting immunosuppression with an extended course of NMF, given at full dosing until day + 150 and then tapered through day + 180, and a shortened course of CSP, through day + 80, would promote tolerance induction and reduce the incidence of GVHD (current patients). We observed 77% grade ll-1V aGVHD and 45% extensive cGVHD (P =.03, and P =.43, respectively, in current compared to historical patients). The 1-year probabilities of relapse, NRM, and PFS were 23%, 29%, and 47%, respectively (P =.89, P =.02, and P =.08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning. (c) 2007 American Society for Blood and Marrow Transplantation
http://hdl.handle.net/2268/22914
10.1016/j.bbmt.2007.05.011

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Articl1668BBMT04.pdfNo commentaryPublisher postprint232.22 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.